Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study

Figures & data

Table 1 Characteristics of study subjects before treatment (mean ± SEM)

Treatment	Age (years)	BMI (kg/m^2)	WOMAC	MPQ
Placebo	51.4±1.2	26.6±0.5	52.7±2.3	51.5±1.09
CFB	48.5±1.6	26.9±0.4	53.5±2.5	49.2±1.04

Abbreviations: BMI, body mass index; CFB, calcium fructoborate; MPQ, McGill Pain Questionnaire; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

Table 2 WOMAC and MPQ scores by group at Day 7 and 14 (AVE ± SD)

	Control (n=30)	CFB (n=30)
WOMAC score
Baseline	52.70±12.66	53.57±13.69
Day 7	44.70±11.79	**40.27±11.44
Day 14	51.03±10.36	*38.17±10.11
MPQ score
Baseline	51.47±5.87	49.17±5.74
Day 7	47.67±6.98	*39.57±5.79
Day 14	47.90±5.86	*36.70±5.58

Notes:

* Significant difference from baseline, P<0.003

** P=0.06.

Abbreviations: AVE, average; CFB, calcium fructoborate; MPQ, McGill Pain Questionnaire; SD, standard deviation; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

Table 3 Treatment effects over time as evaluated by WOMAC and MPQ scores

Treatment day	Estimated effect (95% CI)	P-value
WOMAC score
CFB Day 7	−5.30 (−10.84 to 0.24)	0.0610
CFB Day 14	−13.73 (−19.28 to −8.19)	<0.0001
MPQ score
CFB Day 7	−5.80 (−9.22 to −2.38)	0.0009
CFB Day 14	−8.90 (−12.32 to −5.48)	<0.0001

Abbreviations: CFB, calcium fructoborate; CI, confidence interval; MPQ, McGill Pain Questionnaire; WOMAC, Western Ontario and McMaster Universities Arthritis Index.